Business
Half-year Report
Renalytix plc reported a revenue increase to $1.6 million for the six months ended December 31, 2025, up from $1.3 million in the prior year, alongside a reduction in underlying EBITDA loss due to cost management. The company expanded its reach by adding 58 new practice sites and integrating with five EHR systems, up from two, and initiated eight additional integrations expected to benefit approximately 10,000 patients. A $9.5 million over-subscribed placing was completed at a premium to the prior six-month share price. Post-period, Renalytix is advancing discussions for national distribution partnerships and expects to submit for CE marking by the end of FY26, with CE certification targeted for Q1 FY27. The company anticipates full-year revenue of approximately $4 million. Disclaimer*
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \n \n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nHalf Year Report\n \nLONDON and NEW YORK, 26 March, 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd , is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, announces its Half Year Report for the six months ended 31 December 2025 (\"HY26\").\n \nHighlights include:\n \n· Revenue growth to $1.6 million (H1 FY25: $1.3 million)\n· 58 new practices sites added across four active regions of New York, Texas, Florida and Arizona\n· Expanded to five fully integrated EHR systems for seamless patient identification, ordering and reporting, up from two in the prior year period\n· Additional eight integrations initiated to expand access for approximately 10,000 eligible patients\n\n\n\n\n· Extended data integration pipelines to leading EMR platforms used in primary care setting including Epic Systems, Athenahealth and eClinicalWorks\n\n\n\n\n· Underlying EBITDA loss reduced year-on-year, reflecting disciplined cost management\n· Transition to new laboratory facility commenced to enhance capacity and improve gross margin\n· $9.5m raised through over-subscribed placing and retail offer at a premium to prior 6 month share price \n \nPost period end highlights include:\n \n· Advancing contract discussion with major US diagnostic companies to provide kidneyintelX.dkd with broad, national distribution and reduction in logistics cost for blood sample transport\n· Submission for publication of two year, multi-center Wake Forest Atrium Health and Mount Sinai Health System outcomes data expected to support further guidelines recommendations, expanded commercial insurance coverage and doctor utility\n· CE marking submission progressing, on target for completion of review by end of FY26 and CE certification in Q1-FY27\n· Advancement of program milestones for inclusion of kidneyintelX.dkd in a major pharma drug trial in chronic kidney dise...